Literature DB >> 11248717

Safety and efficacy of heliox as a treatment for upper airway obstruction due to radiation-induced laryngeal dysfunction.

H Khanlou1, G Eiger.   

Abstract

The mixture of helium and oxygen, called heliox, has been successfully used in the management of different respiratory diseases since 1935. Despite several reports on its usefulness, it is not widely available in acute care facilities and it remains somewhat controversial. In this article we present the case of a 69-year-old woman in whom bilateral vocal cord paralysis developed after radiation therapy and in whom heliox was successfully used to manage her upper airway obstruction. Although heliox offers an additional tool in the treatment of various airway and pulmonary problems, it can be used only as a temporizing agent to allow time for appropriate therapy of the underlying process. Given its beneficial physiologic and clinical effects, it seems that further studies are warranted to define a clear and concise protocol for its use in the emergency setting.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11248717     DOI: 10.1067/mhl.2001.112026

Source DB:  PubMed          Journal:  Heart Lung        ISSN: 0147-9563            Impact factor:   2.210


  4 in total

1.  Helium in the adult critical care setting.

Authors:  J-L Diehl; V Peigne; E Guérot; C Faisy; L Lecourt; A Mercat
Journal:  Ann Intensive Care       Date:  2011-07-06       Impact factor: 6.925

Review 2.  Clinical review: use of helium-oxygen in critically ill patients.

Authors:  Marc Gainnier; Jean-Marie Forel
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

3.  The use of heliox in critical care.

Authors:  Seyed Mohammadreza Hashemian; Farahnaz Fallahian
Journal:  Int J Crit Illn Inj Sci       Date:  2014-04

4.  A double-blind, randomised, controlled Phase II trial of Heliox28 gas mixture in lung cancer patients with dyspnoea on exertion.

Authors:  S H Ahmedzai; E Laude; A Robertson; G Troy; V Vora
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.